Cargando…
Ocular surface disease: a known yet overlooked side effect of topical glaucoma therapy
Ocular surface disease (OSD), a disorder affecting the lacrimal and meibomian glands and the corneal and conjunctival epithelium, is a well-known complication of topical glaucoma therapy. OSD can present as a new or pre-existing condition that virtually any anti-glaucoma formulation can exacerbate....
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10403269/ https://www.ncbi.nlm.nih.gov/pubmed/37547228 http://dx.doi.org/10.3389/ftox.2023.1067942 |
_version_ | 1785085031174111232 |
---|---|
author | Ruiz-Lozano, Raul E. Azar, Nadim S. Mousa, Hazem M. Quiroga-Garza, Manuel E. Komai, Seitaro Wheelock-Gutierrez, Lorena Cartes, Cristian Perez, Victor L. |
author_facet | Ruiz-Lozano, Raul E. Azar, Nadim S. Mousa, Hazem M. Quiroga-Garza, Manuel E. Komai, Seitaro Wheelock-Gutierrez, Lorena Cartes, Cristian Perez, Victor L. |
author_sort | Ruiz-Lozano, Raul E. |
collection | PubMed |
description | Ocular surface disease (OSD), a disorder affecting the lacrimal and meibomian glands and the corneal and conjunctival epithelium, is a well-known complication of topical glaucoma therapy. OSD can present as a new or pre-existing condition that virtually any anti-glaucoma formulation can exacerbate. As such, both glaucoma and OSD frequently coexist. Typical OSD symptoms include ocular discomfort, redness, burning, and dryness, whereas signs include periorbital and eyelid skin pigmentation, conjunctival scarring, and superficial punctate keratitis. Pressure-lowering eyedrops can cause toxic, allergic, and inflammatory reactions on the ocular surface. The latter can result from either preservatives or direct toxicity from the active molecule. Although usually mild, OSD can cause significant symptoms that lead to poor quality of life, decreased compliance to therapy, glaucoma progression, and worse visual outcomes. Given the chronic nature of glaucoma, lack of curative therapy, and subsequent lifelong treatment, addressing OSD is necessary. This manuscript aims to provide an up-to-date overview of OSD’s signs, symptoms, and pathogenic mechanisms from glaucoma therapy toxicity. |
format | Online Article Text |
id | pubmed-10403269 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-104032692023-08-05 Ocular surface disease: a known yet overlooked side effect of topical glaucoma therapy Ruiz-Lozano, Raul E. Azar, Nadim S. Mousa, Hazem M. Quiroga-Garza, Manuel E. Komai, Seitaro Wheelock-Gutierrez, Lorena Cartes, Cristian Perez, Victor L. Front Toxicol Toxicology Ocular surface disease (OSD), a disorder affecting the lacrimal and meibomian glands and the corneal and conjunctival epithelium, is a well-known complication of topical glaucoma therapy. OSD can present as a new or pre-existing condition that virtually any anti-glaucoma formulation can exacerbate. As such, both glaucoma and OSD frequently coexist. Typical OSD symptoms include ocular discomfort, redness, burning, and dryness, whereas signs include periorbital and eyelid skin pigmentation, conjunctival scarring, and superficial punctate keratitis. Pressure-lowering eyedrops can cause toxic, allergic, and inflammatory reactions on the ocular surface. The latter can result from either preservatives or direct toxicity from the active molecule. Although usually mild, OSD can cause significant symptoms that lead to poor quality of life, decreased compliance to therapy, glaucoma progression, and worse visual outcomes. Given the chronic nature of glaucoma, lack of curative therapy, and subsequent lifelong treatment, addressing OSD is necessary. This manuscript aims to provide an up-to-date overview of OSD’s signs, symptoms, and pathogenic mechanisms from glaucoma therapy toxicity. Frontiers Media S.A. 2023-07-21 /pmc/articles/PMC10403269/ /pubmed/37547228 http://dx.doi.org/10.3389/ftox.2023.1067942 Text en Copyright © 2023 Ruiz-Lozano, Azar, Mousa, Quiroga-Garza, Komai, Wheelock-Gutierrez, Cartes and Perez. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Toxicology Ruiz-Lozano, Raul E. Azar, Nadim S. Mousa, Hazem M. Quiroga-Garza, Manuel E. Komai, Seitaro Wheelock-Gutierrez, Lorena Cartes, Cristian Perez, Victor L. Ocular surface disease: a known yet overlooked side effect of topical glaucoma therapy |
title | Ocular surface disease: a known yet overlooked side effect of topical glaucoma therapy |
title_full | Ocular surface disease: a known yet overlooked side effect of topical glaucoma therapy |
title_fullStr | Ocular surface disease: a known yet overlooked side effect of topical glaucoma therapy |
title_full_unstemmed | Ocular surface disease: a known yet overlooked side effect of topical glaucoma therapy |
title_short | Ocular surface disease: a known yet overlooked side effect of topical glaucoma therapy |
title_sort | ocular surface disease: a known yet overlooked side effect of topical glaucoma therapy |
topic | Toxicology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10403269/ https://www.ncbi.nlm.nih.gov/pubmed/37547228 http://dx.doi.org/10.3389/ftox.2023.1067942 |
work_keys_str_mv | AT ruizlozanoraule ocularsurfacediseaseaknownyetoverlookedsideeffectoftopicalglaucomatherapy AT azarnadims ocularsurfacediseaseaknownyetoverlookedsideeffectoftopicalglaucomatherapy AT mousahazemm ocularsurfacediseaseaknownyetoverlookedsideeffectoftopicalglaucomatherapy AT quirogagarzamanuele ocularsurfacediseaseaknownyetoverlookedsideeffectoftopicalglaucomatherapy AT komaiseitaro ocularsurfacediseaseaknownyetoverlookedsideeffectoftopicalglaucomatherapy AT wheelockgutierrezlorena ocularsurfacediseaseaknownyetoverlookedsideeffectoftopicalglaucomatherapy AT cartescristian ocularsurfacediseaseaknownyetoverlookedsideeffectoftopicalglaucomatherapy AT perezvictorl ocularsurfacediseaseaknownyetoverlookedsideeffectoftopicalglaucomatherapy |